title: [Oral formulation of choice for children].
abstract: Selecting the most appropriate oral formulation is very challenging when developing medicines for children and in routine practice. Research in pediatric pharmacology has focused on oral drug formulation, determining whether the active pharmaceutical ingredient can be successfully delivered to children. Pediatric expert committees (EMA, EuFPI) recommend that children's medicines be safe, well tolerated, easy to use (palatable and requiring minimal handling), transportable, easily produced, cost effective, commercially viable, with a minimal impact on children's life-style. Oral liquid drug formulations (OLFs: solutions, syrups, suspensions) are historically considered as the most appropriate oral formulation for children, since they are easy to swallow for younger infants and palatable for children. However, OLFs present numerous disadvantages, such as low stability, potentially toxic excipients for children, and low transportability. In the long-term, dose volume and frequency of administration might lead to non-compliance. Multiple preparation steps and volume calculations are also among risk factors for medicine errors in children. An alternative to OLFs is the conventional solid oral dosage form (OSF), such as tablets and capsules. These offer the advantages of greater stability, easy dose selection, improved transportability, and ease of storage. They also allow the modification of drug pharmacokinetic parameters, minimizing administration frequency. Finally, OSFs are less costly than OLFs, since they are easier to develop, manufacture, transport, store, and deliver. Controlled study results suggest that the use of OSFs in children would be associated with greater acceptability by children, greater preference on the part of caregivers, and higher drug compliance than OLFs. Recent controlled studies, confirming that OSFs with an acceptable size for children (mini-tablets), should shift the current paradigm of OLFs as the reference for children's oral medicine. We lack evidence on OSF acceptability in children and its influence on drug compliance, particularly with appropriate-size OSFs for children. Further investigation on oral formulation should investigate the utilisation of OSFs in young children. Few OSFs are licensed for children under 6 years of age.
authors.affiliation: CIC 1407 Inserm, service de pharmacologie clinique, épidémiologie, pharmacologie, investigation clinique et information médicale, mère-enfant (Epicime), centre d'investigation clinique pédiatrique, hospices civils de Lyon, CHU de Lyon, 69677 Bron, France; CNRS UMR 5558, laboratoire de biométrie et biologie évolutive, université Lyon 1, 69000 Lyon, France. Electronic address: audrey.lajoinie@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Lajoinie
authors.affiliation: CIC 1407 Inserm, service de pharmacologie clinique, épidémiologie, pharmacologie, investigation clinique et information médicale, mère-enfant (Epicime), centre d'investigation clinique pédiatrique, hospices civils de Lyon, CHU de Lyon, 69677 Bron, France; CNRS UMR 5558, laboratoire de biométrie et biologie évolutive, université Lyon 1, 69000 Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Henin
authors.affiliation: CIC 1407 Inserm, service de pharmacologie clinique, épidémiologie, pharmacologie, investigation clinique et information médicale, mère-enfant (Epicime), centre d'investigation clinique pédiatrique, hospices civils de Lyon, CHU de Lyon, 69677 Bron, France; CNRS UMR 5558, laboratoire de biométrie et biologie évolutive, université Lyon 1, 69000 Lyon, France.
authors.forename: B
authors.initials: B
authors.lastname: Kassai
mesh_terms: D002626:Chemistry, Pharmaceutical; D002648:Child; D004304:Dosage Forms; D006801:Humans; D055118:Medication Adherence; D057240:Patient Preference
chemical_list: D004304:Dosage Forms